FDA approves Bayer stroke drug and warns on GLP-1 eye risks
The US Food and Drug Administration approved a new Bayer medication for stroke prevention while issuing warnings about rare vision loss linked to weight-loss drugs.
New stroke treatment gains approval
The FDA approved Sunharbo, a novel drug from Bayer, to reduce the recurrence of strokes. This medication represents the first in its class and aims to prevent blood clots safely. Many existing blood thinners carry an increased risk of bleeding for patients in this setting. The new drug uses a specific mechanism that stops bad clot formation without raising bleeding risks. Experts state the data shows a significant advance after little innovation occurred over past decades.
Secondary strokes affect many patients
Secondary strokes are estimated to affect about 20 percent of people who have had a first stroke. These events can cause severe disability or death for the affected individuals. In addition, the FDA cautioned that GLP-1 medications present a possible danger of an uncommon yet severe eye problem. This condition is called non-arteritic anterior ischemic optic neuropathy and is sometimes referred to as an eye stroke. The condition stems from inadequate circulation reaching the optic nerve and usually results in abrupt sight impairment.
Regulators investigate weight-loss drug risks
Following a 2024 observational study that connected Ozempic and Wegovy to an eye condition, the FDA began investigating this risk. Pharmaceutical companies must now inform patients and doctors of the risk associated with these medications. There are currently no proven treatments for the condition if it occurs. The agency requires clear communication regarding these potential side effects for all users.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.